247 related articles for article (PubMed ID: 2445154)
41. Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis.
Risteli J; Søgaard H; Oikarinen A; Risteli L; Karvonen J; Zachariae H
Br J Dermatol; 1988 Sep; 119(3):321-5. PubMed ID: 3179204
[TBL] [Abstract][Full Text] [Related]
42. Morphogenesis of fibrosis and cirrhosis in methotrexate-treated patients with psoriasis.
Nyfors A; Poulsen H
Am J Surg Pathol; 1977 Sep; 1(3):235-43. PubMed ID: 920871
[TBL] [Abstract][Full Text] [Related]
43. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy.
Bray AP; Barnova I; Przemioslo R; Kennedy CT
Br J Dermatol; 2012 May; 166(5):1125-7. PubMed ID: 21967341
[No Abstract] [Full Text] [Related]
44. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity.
McHenry PM; Bingham EA; Callender ME; Delvin PB; O'Hara MD; Ferguson WR; Laird JD; Burrows D
Br J Dermatol; 1992 Aug; 127(2):122-5. PubMed ID: 1390139
[TBL] [Abstract][Full Text] [Related]
45. Hepatotoxicity of methotrexate in the treatment of psoriasis.
Palmer HM
Practitioner; 1973 Sep; 211(263):324-8. PubMed ID: 4759241
[No Abstract] [Full Text] [Related]
46. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?
Aithal GP; Haugk B; Das S; Card T; Burt AD; Record CO
Aliment Pharmacol Ther; 2004 Feb; 19(4):391-9. PubMed ID: 14871278
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of possible chronic hepatotoxicity from methotrexate for psoriasis.
Weinstein GD; Cox JW; Suringa DW; Millard MM; Kalser M; Frost P
Arch Dermatol; 1970 Dec; 102(6):613-8. PubMed ID: 5501902
[No Abstract] [Full Text] [Related]
48. Methotrexate hepatotoxicity in psoriasis--comparison of different dose regimens.
Dahl MG; Gregory MM; Scheuer PJ
Br Med J; 1972 Mar; 1(5801):654-6. PubMed ID: 5015292
[TBL] [Abstract][Full Text] [Related]
49. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics.
Nyfors A
Dan Med Bull; 1978 Oct; 25(5):208-11. PubMed ID: 359259
[No Abstract] [Full Text] [Related]
50. The aminopyrine breath test, an inadequate early indicator of methotrexate-induced liver disease in patients with psoriasis.
Williams CN; McCauley D; Malatjalian DA; Turnbull GK; Ross JB
Clin Invest Med; 1987 Mar; 10(2):54-8. PubMed ID: 3581546
[TBL] [Abstract][Full Text] [Related]
51. Methotrexate in erythrocytes of patients with psoriasis.
Schrøder H; Foged EK
Eur J Clin Pharmacol; 1986; 30(4):453-6. PubMed ID: 3743621
[TBL] [Abstract][Full Text] [Related]
52. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy.
Themido R; Loureiro M; Pecegueiro M; Brandão M; Campos MC
Acta Derm Venereol; 1992 Sep; 72(5):361-4. PubMed ID: 1361285
[TBL] [Abstract][Full Text] [Related]
53. Intestinal folate absorption in methotrexate treated psoriatic patients.
Duhra P; Hodgson C; Martin JA; Stableforth PJ
Br J Dermatol; 1988 Sep; 119(3):327-32. PubMed ID: 3179205
[TBL] [Abstract][Full Text] [Related]
54. Cirrhosis associated with methotrexate treatment of psoriasis.
Coe RO; Bull FE
JAMA; 1968 Nov; 206(7):1515-20. PubMed ID: 5695945
[No Abstract] [Full Text] [Related]
55. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.
Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN
Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271
[TBL] [Abstract][Full Text] [Related]
56. Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes.
Oogarah PK; Rowland PL; Mitchell DM; Smith A; Chalmers RJ; Rowan B; Haboubi NY
Br J Dermatol; 1995 Oct; 133(4):512-8. PubMed ID: 7577576
[TBL] [Abstract][Full Text] [Related]
57. Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?
Thomas JA; Aithal GP
Am J Clin Dermatol; 2005; 6(6):357-63. PubMed ID: 16343024
[TBL] [Abstract][Full Text] [Related]
58. Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis.
Nohlgård C; Rubio CA; Kock Y; Hammar H
J Am Acad Dermatol; 1993 Jan; 28(1):40-5. PubMed ID: 7678843
[TBL] [Abstract][Full Text] [Related]
59. A pragmatic non-invasive assessment of liver fibrosis in patients with psoriasis, rheumatoid arthritis or Crohn's disease receiving methotrexate therapy.
Cervoni JP; Alby-Lepresle B; Weil D; Zhong P; Aubin F; Wendling D; Toussirot E; Vuitton L; Carbonnel F; Blondet R; Thévenot T; Calès P; Monnet E; Di Martino V
Clin Res Hepatol Gastroenterol; 2020; 44S():100003. PubMed ID: 33602481
[TBL] [Abstract][Full Text] [Related]
60. Liver biopsies in psoriatics--complications and evaluation.
Creswell SN; Burrows D
Int J Dermatol; 1980 May; 19(4):217-9. PubMed ID: 7399795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
